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TheOrphanDrug Act encourages the development of products for rare diseases and conditions.Many condi-
tions that stand to benefit from stem cell-based products are rare diseases. We address the Orphan Drug Act
in relation to the development of stem cell-based products.The provisions of the United States (US)
1983Orphan Drug Act (ODA) are intended
to stimulate the development of pro-
ducts for rare diseases and conditions
(henceforth referred to collectively as
rare diseases) (USFDA, 1983, as revised).
The US Food and Drug Administration
(FDA) Office of Orphan Products Develop-
ment (OOPD) is charged with implement-
ing the act. We have reviewed all stem
cell-based product (SCBP; defined as
adult, embryonic or fetal-derived stem
cells or progenitor cells) applications
received by our office that have been
granted an orphan designation. In this
article, we evaluate what has been deliv-
ered through the ODA and its specific
contributions toward SCBPs for rare
diseases. Overall, this article focuses
on issues related to SCBPs and rare
diseases and ramifications of the ODA
with respect to advancing the field of
investigational clinical research involving
SCBPs.
The US enacted the ODA in 1983 in
response to a deficiency in the identifi-
cation, development, and availability of
products (drugs, biologics, and devices)
intended for rare diseases (USFDA,
1983, as revised). The provisions of the
act seek to reverse this insufficiency by
extending incentives designed to counter
fiscal challenges impeding development.
These incentives include 7 years of
market exclusivity, tax credits for 50% of
clinical development costs (for US
studies), and an exemption from user
fees—the fee for submission of a market-
ing application for review ($1,405,500 for
applications requiring clinical data for
FY2010) (Orphan Drug Regulations,
2004; USFDA, 1983, as revised). In addi-
tion to these enticements, an independentOrphan Products Grants Program exists
that provides funding for the clinical
development of products indicated for
rare diseases.
It is important to note that the 7 year
market exclusivity provision differs from
patent protection. Seven-year market
exclusivity is available for products that
may receive a patent or are unable to
become patented. Whereas patent pro-
tection prevents the usage of the active
component of the product for any indica-
tion, 7 years of market exclusivity runs
concurrent with any patented entity
and protects the specific product active
component for a specific rare condition
(e.g., another sponsor may market the
entity—if not patented—for a different
‘‘common’’ or rare disease) (Orphan
Drug Regulations, 2004; USFDA, 1983,
as revised). This protects products
explored for rare diseases that are not
under patent protection and may not
qualify for patent protection.
To be eligible for these incentives
(minus the Orphan Products Grants Pro-
gram), a sponsor must first receive
an orphan designation for their product.
Qualification for an orphan designation
requires demonstration that the indication
for the product constitutes a rare disease
(US prevalence <200,000) and that there
is sufficient evidence of medical rationale
to expect that the product is promising
for the treatment of the given indication
(Orphan Drug Regulations, 2004; USFDA,
1983, as revised). This evidence may be
obtained from preclinical studies utilizing
a suitable model system or results from
clinical evaluation.
The ODA has contributed to the devel-
opment of products for rare diseases
that may have otherwise never come toCell Stem Cell 7, Srealization. Many of the products are
indicated for diseases that were without
a viable treatment option or treatment(s)
of limited effectiveness. As of March 31,
2010, the OOPD received 3094 applica-
tions for orphan designation and from
this granted 2156 designations (70%
of all applications) (USFDA, 2010d)
(Figure 1A; through 2009). During this
period, 349 orphan-designated products
(n = 346 through 2009 per Figure 1)
received marketing approval (16% of all
orphan designated products). At present,
orphan-designated products comprise
approximately one-third of all FDA
New Molecular Entity (NME) marketing
approvals (Cote´ et al., 2010). As shown
in Figure 1A, orphan product applica-
tions and designations have been
steadily increasing. These data demon-
strate an increase in the orphan drug
sector and an acceleration in resources
allocated to drug development for rare
diseases.
From the inception of the ODA in
1983 through March 31, 2010, the OOPD
received 27 applications for orphan des-
ignation of SCBPs with none receiving
marketing approval (USFDA, 2010d). The
27applicationsyielded21orphandesigna-
tions (78%; slightly greater than the rate of
designation for orphan product applica-
tions collectively), three denials, two with-
drawals, and one that was pending
a response. Please note that n = 18 desig-
nations in Figure 1B because the graph
only includes designations in which data
were available for the entire year. Table 1
provides a synopsis of all orphan-desig-
nated SCBPs and information regarding
their respective sponsor descriptions,
tradenames, designated indication, desig-
nation date, and sponsor as obtained fromeptember 3, 2010 ª2010 Elsevier Inc. 283
AB
Figure 1. Orphan Product Applications, Designations, and Marketing Approvals and Stem
Cell-Based Product Orphan Designations
(A) The quantities of orphan product applications, designations, and approvals collectively from 1983–
2009 stratified by year class intervals.
(B) Stem cell-based product orphan designations by year from 1983–2009.
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Product Designation Database (USFDA,
2010c). The first orphan designations for
SCBPs were granted in 1996—after which
there were no designations until singular
designations in both 2001 and 2002
(Figure 1B). After an additional two years
without designations (2003 and 2004),
there were sporadic designations that are
potentially indicative of increased interest
in the years thereafter. Although 2010
was omitted from the graph, there have
thus far been threedesignations forSCBPs284 Cell Stem Cell 7, September 3, 2010 ª20between January and March 31. An inves-
tigation of the proportion of SCBPs that
have advanced into the Investigational
NewDrug (IND)applicationphaseand their
respective stages of development indi-
cates that orphan SCBPs are an active
area of clinical research (USFDA, 2010b).
Specific information on the number on
orphan-designated SCBPs with active
INDs and the stage of development cannot
be provided.
As illustrated in Table 1, orphan-desig-
nated SCBPs originate from various10 Elsevier Inc.sources. These sources include human
embryonic stem cells, fetal porcine cells,
peripheral blood, umbilical cord blood,
mesenchymal tissue, olfactory tissue,
and bone marrow. The diverse sources
of SCBPs are a reflection of the multiple
avenues being utilized to reach the goal
of developing SCBPs. The conditions for
which these SCBPs are being utilized
include neurodegenerative/neuromus-
cular disorders, hematopoietic reconstitu-
tionandsupport, graft versushost disease
(GVHD), ocular diseases, immunodefi-
ciencies, cardiac injury and spinal cord
injury. Hence, SCBPs are being devel-
oped for a wide variety of rare diseases.
Per the ODA, an orphan designation
through the FDA is not limited to sponsors
residing within the US. Indeed, the FDA
and European Medicines Agency (EMA)
have adopted a common orphan product
annual report to facilitate the international
development of products for rare diseases
(USFDA, 2010a). In examining the origin of
orphan applications for SCBPs from 1983
through March 31, 2010, it is evident that
the majority were submitted by sponsors
residing within the US—with 21 applica-
tions submitted by US sponsors and six
originating from international sponsors.
This highlights an underutilized area of
opportunity for international sponsors to
capitalize on US incentives offered
through the ODA for the development of
SCBPs for rare diseases.
SCBPs offer hope for the treatment of
diseases that require the replacement,
renewal, restoration, or regeneration of
damaged or diseased cells or tissues, as
well as neurotrophic support. Some dis-
ease classes in which these products
could prove beneficial include (but are
not limited to) neurodegenerative dis-
eases, malignancies, neuromuscular dis-
orders, spinal cord injury, diabetes, ocular
diseases or injury, heart disease, stroke,
orthopedic diseases or injury, inborn
errors of metabolism, and wound healing.
Within some of these classes reside
a multitude of rare diseases that could
potentially benefit from SCBPs—some of
which are listed in Table 1. Indeed, some
SCBPs are currently under preclinical
or clinical investigation as therapeutics
for rare diseases. Although an exhaustive
list of rare diseases that stand to ben-
efit from such therapies is impractical,
some notable examples include amyotro-
phic lateral sclerosis (ALS), Huntington’s
Table 1. Orphan-Designated Stem Cell-Based Products—1983 to March 31, 2010
Sponsor’s Description Trade Name Designated Indication
Designation
Date Sponsor
Porcine fetal neural GABAergic cells
and/or precursors aseptically prepared
and coated with anti-Mhc-1 Ab For
intracerebral implantation
Neurocell-Hd Treatment of Huntington’s disease 12/10/1996 Diacrin/Genzyme LLC
Porcine fetal neural GABAergic cells
and/or precursors aseptically prepared
for intracerebral implantation for
Huntington’s disease
Neurocell-Hd Treatment of Huntington’s disease 12/10/1996 Diacrin/Genzyme LLC
Porcine fetal neural dopaminergic cells
and/or precursors aseptically prepared
and coated with anti-mhc-1 ab for
intracerebral implantation
Neurocell-Pd Treatment of Hoehn and Yahr stage 4
and 5 Parkinson’s disease
12/17/1996 Diacrin/Genzyme LLC
Porcine fetal neural dopaminergic cells
and/or precursors aseptically prepared
for intracerebral implantation
Neurocell-Pd Treatment of Hoehn and Yahr stage 4
and 5 Parkinson’s disease
12/17/1996 Diacrin/Genzyme LLC
T cell-depleted stem cell enriched
cellular product from peripheal blood
stem cells
N/A Treatment of chronic granulomatous
disease
11/1/2001 Nexell Therapeutics, Inc.
Cells produced using the
AastromReplicelle System and SC-I
Therapy Kit
N/A For use in patients receiving high dose
chemotherapy who are unable to
generate an acceptable dose of
peripheral blood stem cells and who
have a sufficient bone marrow aspirate
without morphological evidence of
tumor
7/10/2002 Aastrom Biosciences, Inc.
Stem and progenitor cells derived from
ex vivo expanded allogeneic umbilical
cord blood
StemEx For use as hematopoietic support in
patients with relasped or refractory
hematologic malignancies who are
receiving high-dose therapy
3/4/2005 Gamida Cell, Ltd.
Autologous or allogeneic limbal
epithelial stem cells expanded ex vivo
on human amniotic membrane
N/A Treatment of ocular surface diseases
that are characterized by total limbal
stem cell deficiency
7/14/2005 TissueTech, Inc.
Ex vivo cultured adult human
mesenchymal stem cells
Prochymal Treatment of acute graft versus
host disease
12/14/2005 Osiris Therpeutics, Inc.
Tissue repair cells obtained from
autologous bone marrow expanded ex
vivo with a cell production system
N/A Treatment of osteonecrosis 3/13/2006 Aastrom Biosciences, Inc.
Human umbilical tissue-derived cells N/A Treatment of retinitis pigmentosa 3/13/2006 Centocor, Inc.
Tissue repair cells obtained from
autologous bone marrow expanded ex
vivo with a cell production system
N/A Treatment of dilated cardiomyopathy 1/25/2007 Aastrom Biosciences, Inc.
Autologous olfactory neural progenitors Rhinocytes Treatment of spinal cord injury patients
with ASIA Impairment grades A, B, or C
2/1/2008 RhinoCyte, Inc.
Human autologous bone-forming cell
derived from bone marrow stem cells
N/A Treatment of osteonecrosis 3/24/2008 Bone Therapeutics S.A.
Allogeneic mesenchymal precursor
cells derived from ex vivo healthy
donors harvested from iliac crest
N/A Treatment of insufficient hematopoietic
stem cell production in patients with
hematologic malignancies who have
failed treatment with conventional
chemotherapy
9/12/2008 Angioblast Systems, Inc.
ALD-101 N/A To improve patient outcomes by
decreasing time to platlet and neutrophil
engraftment in patients with inherited
metabolic diseases (IMD) undergoing
umbilical cord blood transplantation.
10/23/2008 Aldagen, Inc.
(Continued on next page)




Sponsor’s Description Trade Name Designated Indication
Designation
Date Sponsor
Autologous olfactory neural progenitors Rhinocytes Treatment of amyotrophic lateral
sclerosis
12/31/2008 RhinoCyte, Inc.
Late-stage human motor neuron
progenitors
Motorgraft (Tm) Treatment of spinal muscular atrophy 11/25/2009 California Stem Cell, Inc.
Allogeneic ex vivo expanded unbilical
cord blood cells
Stemex For use as hematopoietic support
in patients with chronic myeloid
leukemia
2/1/2010 Gamida Cell Teva Joint Venture
Allogeneic ex vivo expanded unbilical
cord blood cells
Stemex For use as hematopoietic support
in patients with myelodysplastic
syndromes
2/1/2010 Gamida Cell Teva Joint Venture
Ma09-Hrpe Cells N/A Treatment of Stargardt’s macular
dystrophy
2/2/2010 Advanced Cell Technology, Inc.
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Forumdisease, myotonic dystrophy, and retinitis
pigmentosa.
The investigation and development
of SCBPs for the treatment of rare dis-
eases presents an invaluable opportunity
for sponsors to benefit from incentives
offered through the ODA and a means to
potentially advance SCBPs as a whole.
However, of greatest importance is that
it could help hasten the development of
products for often neglected populations
where therapies may be nonexistent or
of limited effectiveness. Many diseases
that stand to benefit from SCBPs are
due to heterogeneous underlying causes,
yet the end clinical pathology of such
disparate maladies may be compa-
rable—as in the case of some neurode-
generative diseases. From this it stands
to reason that research conducted on
SCBPs under the context of a rare
disease (utilizing ODA incentives) may
aid in the development of SCBPs for other
rare or common diseases that manifest
with similar pathologies. Some common-
alities researched on a singular rare
disease that could be translated to
other rare or common diseases include
methods of ex vivo propagation and
differentiation, techniques to control
tumorigenicity or immunogenicity, analyt-
ical tools to characterize as well as
confirm the identity of the final product,
methodologies for (re)introduction of
SCBPs that ensure directed delivery to
their appropriate physiologic locations,
and the development of technologies
that permit noninvasive imaging to allow
for monitoring of the fate of SCBPs after
patient administration. Additionally, the
experimental results obtained from such286 Cell Stem Cell 7, September 3, 2010 ª20studies could help guide other investiga-
tions away from approaches that are
acknowledged by the research commu-
nity as inferior or ineffective and toward
those that display a preferable outcome.
While SCBPs represent promising can-
didates for the treatment of debilitating
diseases, the enthusiasm surrounding
their use must be tempered by the reality
of regulatory expectations that must be
addressed to ensure their safety prior to
human use. Multiple excellent reviews
have comprehensively addressed this
subject matter, and the reader is encour-
aged to refer to these manuscripts to
acquire a greater appreciation of the
challenges involved in SCBP regulation
(Carpenter et al., 2009; Fink, 2009; Halme
and Kessler, 2006). Given this, regulatory
and safety issues will only be briefly dis-
cussed. SCBPs are inherently complex
biologics and their use for a spectrum
of heterogeneous applications, as well
as further manipulation, compounds this
complexity. The very attributes exhibited
by SCBPs that bestow their putative
therapeutic utility, namely self-renewing
proliferation and the capacity to assume
the specialized properties of multiple cell
types, is a double-edged sword that also
serves as the source of safety concerns
and regulatory challenge. As previously
published, such safety concerns include
the capacity for residual undifferentiated
cells present in a cellular product to prolif-
erate and form teratomas, the potential
for malignant transformation to occur,
migration of cells from the intended
site of delivery to anatomically sensitive
nontarget locations, immunogenicity that
is due to immunological disparities10 Elsevier Inc.between the cellular product and recip-
ient, allodynia, and the presence of unde-
sired cellular impurities within the final
product (Fink, 2009; Hofstetter et al.,
2005). These issues currently receive
careful scrutiny during the review of IND
applications for SCBPs and must be fully
addressed to demonstrate a reasonable
level of safety for human subjects partici-
pating in clinical investigations.
The initiation of studies and develop-
ment of products under the auspices of
the ODA typically begins with an orphan
product designation. However, an orphan
designation may be granted at anytime
during development prior to the submis-
sion of a New Drug Application (NDA) or
Biologic License Application (BLA). ODA
assistance for the funding of clinical
studies may be obtained through the
Orphan Products Grants Program. Other
support that may be provided to sponsors
per the ODA include communication
with FDA and review divisions in which
protocol assistance is provided for con-
structing a plan for product development
(Orphan Drug Regulations, 2004; USFDA,
1983, as revised).
The scope of the ODA includes SCBPs
for rare diseases. The provisions of the
ODA have had a positive effect on pro-
moting the development of products for
rare diseases including those amenable
to SCBP therapies. Active INDs and
increased orphan designations demon-
strate that SCBPs are an active area of
clinical research and that there is an
increased interest by sponsors in pursu-
ing SCBPs for rare diseases, respectively.
The diversity of SCBP sources and their
respective disease indications indicate
Cell Stem Cell
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from multiple angles for a variety of mal-
adies. Additionally, research conducted
on SCBPs for rare diseases under the
support of the ODA may yield data that
could be translated toward research
into SCBPs for other rare or common
diseases. Finally, given the complexity of
such biologics, regulatory issues that
address preclinical safety and efficacy
and the selection of appropriate patient
populations must be considered prior to
first-in-human studies. These concerns
can be addressed via early communica-
tion with the FDA review division. In
summary, we have explored and postu-
lated how the ODA might be used to facil-
itate development of SCBPs for rare
diseases and the potential for a broader
impact on clinical investigation of SCBPs
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